Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing.
Petra PokornaGiannoula Lakka KlementAlzbeta VasikovaVeronika KanderovaMarta JezovaKristyna NoskovaPeter MudryMichal KyrTomas MertaViera BajciovaZdenka KrenovaHana PalovaDalibor ValikLenka Zdrazilova DubskaOndrej SlabyJaroslav SterbaPublished in: JCO precision oncology (2022)